Early clinical observations indicated substantial reductions in liver fat content, prompting interest in the compound as a research tool for studying metabolic-associated steatotic liver disease (MASLD)
Branded FDA-Approved Option (Alternative) For patients who prefer FDA-approved branded medications, we are happy to prescribe Ozempic, Wegovy, Mounjaro, or Zepbound at manufacturer pricing
Final dosing will be confirmed after approval
Your GI tract needs time to adjust
Between the index date and the first weight change recorded date, the patient is considered unknown in terms of weight change
2+ /calmodulin (CaM)-dependent protein kinase kinase/CAM-dependent protein kinase IV/Prolactin regulatory element binding (CaMKK/CaMKIV/PREB), increasing apolipoprotein AI (apo AI) mRNA and promoter expression, and increasing apo AI secretion, thereby mediating intracellular cholesterol efflux